2024-03-29T00:27:09Z
https://tsukuba.repo.nii.ac.jp/oai
oai:tsukuba.repo.nii.ac.jp:00055766
2022-04-27T09:30:35Z
2780:2965
3:62:5593:8061
Catheter Ablation for Brugada Syndrome
野上, 昭彦
ノガミ, アキヒコ
NOGAMI, Akihiko
Talib, Ahmed Karim
© 2020. The Korean Society of Cardiology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Brugada syndrome (BrS) is an arrhythmogenic disease associated with an increased risk of ventricular fibrillation (VF) and sudden cardiac death (SCD). To date, the standard therapy for the prevention of SCD in BrS is the use of an implantable cardioverter-defibrillator (ICD) especially in patients who have experienced a prior cardiac arrest or syncopal events secondary to VF. However, ICDs do not prevent the occurrence of VF but react to defibrillate the VF episode, thereby preventing SCD. Often patients with recurrent VF have to be maintained on antiarrhythmic drugs that are effective but have remarkable adverse effects. An alternative therapy for BrS with recurrent VF is catheter ablation which emerged as an effective therapy in eliminating VF-triggering premature ventricular complexes in limited case series; however, there has been a remarkable progress in effectiveness of catheter ablation since epicardial substrate ablation was first applied in 2011 and such approach is now widely applicable.
Korean Society Cardiology
2020-04
eng
journal article
http://hdl.handle.net/2241/00161170
https://tsukuba.repo.nii.ac.jp/records/55766
31960637
10.4070/kcj.2019.0344
1738-5520
AA12144400
Korean circulation journal
50
4
289
https://tsukuba.repo.nii.ac.jp/record/55766/files/KCJ_50-4.pdf
application/pdf
8.2 MB
2020-09-04